Formats
  1. Journal Article (67270)
  2. Meeting Abstract (33961)
  3. Book Section (5131)
  4. Review (3869)
  5. Editorial (2245)
  6. Conference Paper (1528)
  7. Guidelines (686)
  8. Correspondence (679)
  9. Research Letter (565)
  10. Book Whole (346)
  11. Miscellaneous (344)
Groups
  1. Department of Medicine (39470)
  2. GSK Faculty (22632)
  3. Solid Tumor Oncology Division (22264)
  4. Surgery (21420)
  5. Survivorship Research (15905)
  6. Sloan Kettering Institute Faculty (15715)

More Groups

People
  1. Marc Ladanyi (1332)
  2. Robert Motzer (1247)
  3. Victor Reuter (1230)
  4. Howard Scher (1130)
  5. Sergio Giralt (1065)
  6. Murray Brennan (1059)

More People

Years
  1. 2026 (7)
  2. 2025 (2927)
  3. 2024 (5602)
  4. 2023 (5809)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. Blood (5173)
  3. Cancer Research (2703)
  4. International Journal of Radiation Oncology, Biology, Physics (2621)
  5. Laboratory Investigation (1890)
  6. Modern Pathology (1817)

More Publications

Publishers
  1. Elsevier Inc. (13955)
  2. American Society of Clinical Oncology (9291)
  3. Springer (7231)
  4. Nature Publishing Group (6443)
  5. American Association for Cancer Research (6026)
  6. Elsevier Science, Inc. (5556)

More Publishers

Results (116624)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An end-of-study subgroup analysis of black patients from the phase 2 griffin study of daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y. A.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A. Z.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin (Belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Kotowsky, N.; Bitetti, J.; Mackay, C.; Boytsov, N.; Camadoo-O'Byrne, L.; Germain, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: MAIA age subgroup analysis
    Meeting Abstract

    Facon, T.; Kumar, S. K.; Weisel, K.; Usmani, S.; Moreau, P.; Plesner, T.; Orlowski, R. Z.; Bahlis, N. J.; Basu, S.; Nahi, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the griffin and master studies
    Meeting Abstract

    Callander, N.; Silbermann, R.; Kaufman, J. L.; Godby, K. N.; Laubach, J. P.; Schmidt, T. M.; Sborov, D. W.; Medvedova, E.; Reeves, B.; Dhakal, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Hypercalcemia in individuals with monoclonal gammopathy of undetermined significance: Results from the iStopMM study
    Meeting Abstract

    Jónsdóttir, Á. H.; Rögnvaldsson, S.; Sigurjónsdóttir, H. Á.; Thorsteinsdóttir, S.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardóttir, M.; Thorsteinsdottir, I.; Ólafsson, Í.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas
    Meeting Abstract

    Fregonese, B.; Dreyfuss, A.; Lee, J.; Imber, B. S.; Yahalom, J.; Hajj, C.
    Blood (2022)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance and risk of chronic kidney disease: results of the population-based Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Long, T. E.; Eythorsson, E.; Rognvaldsson, S.; Indridason, O.; Palsson, R.; Thorsteinsdóttir, S.; Sverrisdottir, I. S.; Aspelund, T.; Vidarsson, B.; Onundarson, P. T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Monoclonal gammopathy of undetermined significance (MGUS) with multiple paraproteins: Results from the population-based iStopMM screening study
    Meeting Abstract

    Rögnvaldsson , S.; Oskarsson, J. Þ.; Thorsteinsdottir, S.; Reed, E. R.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Sigurdardottir, M.; Agnarsson, B. A.; Olafsson, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Autoimmune diseases are not associated with monoclonal gammopathy of undetermined significance: Results of the prospective population-based iStopMM study
    Meeting Abstract

    Sverrisdottir, I. S.; Thorsteinsdóttir, S.; Rögnvaldsson, S.; Aspelund, T.; Vidarsson, B.; Önundarson, P. T.; Agnarsson, B.; Sigurdardóttir, M.; Thorsteinsdottir, I.; Sveinsdottir, S. V.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Geometric network analysis defines poor-prognosis subtypes in multiple myeloma
    Meeting Abstract

    Simhal, A. K.; Maclachlan, K. H.; Elkin, R.; Zhu, J.; Usmani, S.; Keats, J. J.; Norton, L.; Deasy, J. O.; Oh, J. H.; Tannenbaum, A.
    Blood (2022)

    Fulltext@MSK | Save